CN103910781B - 一种Aβ聚集抑制剂 - Google Patents

一种Aβ聚集抑制剂 Download PDF

Info

Publication number
CN103910781B
CN103910781B CN201410100093.5A CN201410100093A CN103910781B CN 103910781 B CN103910781 B CN 103910781B CN 201410100093 A CN201410100093 A CN 201410100093A CN 103910781 B CN103910781 B CN 103910781B
Authority
CN
China
Prior art keywords
aggregation inhibitor
beta peptide
peptide
peptide aggregation
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410100093.5A
Other languages
English (en)
Other versions
CN103910781A (zh
Inventor
梁桂兆
肖会芝
钱宇
郑洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing University
Original Assignee
Chongqing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing University filed Critical Chongqing University
Priority to CN201410100093.5A priority Critical patent/CN103910781B/zh
Publication of CN103910781A publication Critical patent/CN103910781A/zh
Application granted granted Critical
Publication of CN103910781B publication Critical patent/CN103910781B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

本发明公开了一种Aβ聚集抑制剂,其特征在于它的氨基酸序列为:氨基端-CTIWYG-羧基端。本肽序列经原子力显微镜扫描技术检测,进一步用细胞毒性实验评价得到。它对导致阿尔茨海默病的主要毒性体-Aβ的聚集具有良好的抑制作用,可尝试开发为阿尔茨海默病治疗药物。

Description

一种Aβ聚集抑制剂
技术领域
本发明涉及一种Aβ聚集抑制剂,特别是一种抗阿尔茨海默病的毒性体Aβ抑制剂。
背景技术
目前,全球至少有3500万人患有阿尔茨海默病,且每年的致死率正在上升。每年全球的总花费估计达到2000亿美元,研究表明,Aβ(Amyloidβ-peptide)寡聚体是老年痴呆症病人体内的显著毒性体,因此抑制Aβ寡聚体的生成是阻止老年痴呆症发生最有效的策略。然而,目前无有效方法用于Aβ抑制剂设计,主要面对三方面的严重挑战:1、缺少有效的高通量筛选方法:实验筛选方法需要合成和纯化Aβ,这对于大量化合物的筛选无疑是费时、昂贵且不现实。2、缺少Aβ寡聚体的高分辨率结构:Aβ寡聚体呈亚稳态,因此利用X-射线衍射和NMR技术很难得到其结构,使基于结构的合理药物设计难以实现。3、缺少对Aβ自组装机制的理解:包括肽的哪一部分构成在淀粉样纤维生成过程中起着关键作用;种子和纤维生成相关的路径与中间体是什么;Aβ是否亲和到特定的受体;Aβ如何生成毒性体以及毒性的机制是什么。因此,设计新型Aβ抑制剂对老年痴呆症诊断和治疗具有重要的实践意义。
发明内容
有鉴于此,为了解决上述问题,本发明提供了一种Aβ聚集抑制剂,它的氨基酸序列为:氨基端-CTIWYG-羧基端,可尝试开发为抗阿尔茨海默病治疗药物。
附图说明
为了使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明作进一步的详细描述,其中:
图1是新设计肽CTIWYG对Aβ抑制作用的原子力显微镜扫描结果。
具体实施方式
1)肽对Aβ抑制作用的原子力显微镜扫描实验;
用单光束硅悬臂探测器,在轻敲模式(TappingMode)模式下测定,至少扫描4个区域以确保结构正确采样。图1为新设计肽CTIWYG对Aβ抑制作用的原子力显微镜扫描结果,可看出,经过2天,CTIWYG对Aβ具有明显的抑制作用。此肽可作为Aβ聚集抑制剂,其序列为:氨基端-CTIWYG-羧基端。
图1新设计肽CTIWYG对Aβ抑制作用的原子力显微镜扫描结果(Tapping模式,A为对照实验(无抑制剂),Aβ的浓度为1μm,B中Aβ的浓度为20μM,六肽的浓度为50μM,存放2天,37℃)。
e)细胞毒性试验;
用Polyanionicdyecalcein对活细胞进行绿色荧光标记,并测定其活性,ethidium-1染色对死细胞进行红色荧光标记。相对于由Aβ导致的细胞失活,加入CTIWYG和新制备的Aβ与细胞共同培养后,对应的死亡与成活细胞率为0.412,相对于没有加入肽的对照实验可明显地减少细胞凋亡。当肽与存放24小时的Aβ溶液与细胞进行混合后,经检测得到死与活细胞比率为0.780。
以上所述仅为本发明的优选实施例,并不用于限制本发明,显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
<110>重庆大学
<120>一种Aβ聚集抑制剂
<140>
<141>
<160>1
<210>1
<211>6
<212>PRT
<213>人工序列
<220>
<223>
<400>1
CysThrIlePheTyrGly
15

Claims (1)

1.一种Aβ聚集抑制剂,其特征在于它的氨基酸序列为:氨基端-CTIWYG-羧基端。
CN201410100093.5A 2014-03-18 2014-03-18 一种Aβ聚集抑制剂 Expired - Fee Related CN103910781B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410100093.5A CN103910781B (zh) 2014-03-18 2014-03-18 一种Aβ聚集抑制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410100093.5A CN103910781B (zh) 2014-03-18 2014-03-18 一种Aβ聚集抑制剂

Publications (2)

Publication Number Publication Date
CN103910781A CN103910781A (zh) 2014-07-09
CN103910781B true CN103910781B (zh) 2016-02-17

Family

ID=51036828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410100093.5A Expired - Fee Related CN103910781B (zh) 2014-03-18 2014-03-18 一种Aβ聚集抑制剂

Country Status (1)

Country Link
CN (1) CN103910781B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676065A (zh) * 2018-05-24 2018-10-19 华南理工大学 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131975A1 (en) * 2008-04-22 2009-10-29 Schering Corporation Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
WO2010098487A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2011044181A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN102180947A (zh) * 2011-02-25 2011-09-14 重庆大学 一种Aβ聚集抑制剂
CN102218055A (zh) * 2010-08-31 2011-10-19 南京大学医学院附属鼓楼医院 一种治疗阿尔茨海默病的药物
CN102516359A (zh) * 2011-12-08 2012-06-27 重庆大学 一种新型抗老年痴呆症先导化合物
CN102675419A (zh) * 2011-03-16 2012-09-19 上海博智生物科技有限公司 一种Aβ短肽聚合抑制剂及其制备与应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131975A1 (en) * 2008-04-22 2009-10-29 Schering Corporation Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
WO2010098487A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2011044181A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN102218055A (zh) * 2010-08-31 2011-10-19 南京大学医学院附属鼓楼医院 一种治疗阿尔茨海默病的药物
CN102180947A (zh) * 2011-02-25 2011-09-14 重庆大学 一种Aβ聚集抑制剂
CN102675419A (zh) * 2011-03-16 2012-09-19 上海博智生物科技有限公司 一种Aβ短肽聚合抑制剂及其制备与应用
CN102516359A (zh) * 2011-12-08 2012-06-27 重庆大学 一种新型抗老年痴呆症先导化合物

Also Published As

Publication number Publication date
CN103910781A (zh) 2014-07-09

Similar Documents

Publication Publication Date Title
Nie et al. Quantum sensing of free radicals in primary human dendritic cells
Baek et al. Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time
Krstic et al. Long-range distance measurements on nucleic acids in cells by pulsed EPR spectroscopy
Bousejra-ElGarah et al. Iron (II) binding to amyloid-β, the Alzheimer’s peptide
Cavallari et al. Metabolic Studies of Tumor Cells Using [1‐13C] Pyruvate Hyperpolarized by Means of PHIP‐Side Arm Hydrogenation
Bobylev et al. Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity
Luo et al. Emodin inhibits human sperm functions by reducing sperm [Ca2+] i and tyrosine phosphorylation
Hu et al. Blockade of acid-sensing ion channels protects articular chondrocytes from acid-induced apoptotic injury
Kakinen et al. Single-molecular heteroamyloidosis of human islet amyloid polypeptide
CN101505802A (zh) 含有乳酸盐类和超极化的13c-丙酮酸盐的成像介质
CN105237628B (zh) 一种用于治疗阿尔兹海默症的多肽
Verdurand et al. Differential effects of amyloid-beta 1–40 and 1–42 fibrils on 5-HT1A serotonin receptors in rat brain
Kubíček et al. Towards MRI contrast agents responsive to Ca (II) and Mg (II) ions: Metal‐induced oligomerization of dota–bisphosphonate conjugates
Ding et al. Rapidly Signal‐enhanced Metabolites for Atomic Scale Monitoring of Living Cells with Magnetic Resonance
CN103910781B (zh) 一种Aβ聚集抑制剂
CN103992379B (zh) 一种Aβ聚集抑制剂
CN103910782B (zh) 一种Aβ聚集抑制剂
Chen et al. Hydrogenated germanene nanosheets as an antioxidative defense agent for acute kidney injury treatment
Lee et al. n-Butylidenephthalide modulates autophagy to ameliorate neuropathological progress of spinocerebellar ataxia type 3 through mTOR pathway
Parthiban et al. Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells
CN103992380B (zh) 一种Aβ聚集抑制剂
CN103449477A (zh) 新纳米材料造影剂及其应用
US8933118B2 (en) Anti-brain-tumor drug
CN102516359B (zh) 一种抗老年痴呆症先导化合物
CN108272791A (zh) 漆黄素在制备抑制Tau蛋白异常聚集的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160217

Termination date: 20170318